Compound overview
Tirzepatide: a dual GIP/GLP-1 research overview
Tirzepatide is a synthetic dual-incretin peptide that acts as an agonist at both the GLP-1 and GIP receptors. Its dual-receptor profile made it a benchmark compound in incretin research.
Dual-receptor mechanism
Tirzepatide engages two incretin receptors simultaneously, the GLP-1 and GIP receptors, which distinguishes it from single-receptor GLP-1 agonists.
Comparative incretin research
It is the dual-agonist reference point against which single-agonist semaglutide and triple-agonist retatrutide are compared.
Research models
It is widely referenced across metabolic and endocrine research models.
This overview is provided for educational and laboratory-research purposes only. It summarises published research and proposed mechanisms; it is not medical advice and does not describe or recommend human or veterinary use. Products are supplied strictly for laboratory research use only — not for human or veterinary consumption, and not a drug, food or cosmetic.